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Temporary losartan or captopril in young SHR induces malig-
nant hypertension despite initial normotension.
Background. Exposure of normotensive rats to angiotensin-
converting enzyme (ACE) inhibitors in early life causes hyper-
trophy of intrarenal arteries. Similar defects have been found in
knockout mice lacking angiotensinogen, ACE, or angiotensin II
type 1 (AT1) receptors. On the other hand, transient inhibition
of the renin-angiotensin system from 2 weeks of age in sponta-
neously hypertensive rats (SHR), either with ACE inhibitors or
with AT1 receptor antagonists partially prevents the increase in
blood pressure. However, permanent treatment of SHR from
conception onwards with ACE inhibitors completely prevents
hypertension. Although these studies demonstrated protection
from hypertension-induced changes in the heart and large arter-
ies, renal arteries were not studied and follow-up did not extend
beyond 6 months of age. We postulated that while brief expo-
sure to ACE inhibitors or AT1 receptor antagonists in young
SHR would temporarily decrease blood pressure, it would also
be associated with development of intrarenal arterial malfor-
mation, and ultimately have deleterious effects.
Methods. Direct effects on intrarenal arterial morphology of
an ACE inhibitor (captopril, 100 mg/kg/day) and an AT1 re-
ceptor antagonist (losartan, 50 mg/kg/day), administered from
the last week of gestation until 8 weeks of age were examined
in SHR. After stopping treatment at 8 weeks, we continued to
monitor blood pressure until spontaneous death.
Results. Systolic blood pressure at 8 weeks was normalized
by captopril and losartan (SHR control 187 ± 8 mm Hg; capto-
pril 118 ± 5 mm Hg; and losartan 120 ± 9 mm Hg). However,
by 30 weeks, blood pressure had increased to control SHR lev-
els. At 4 weeks, the media of renal arteries and arterioles was
hypertrophied. Marked smooth muscle cell hyperplasia of cor-
tical arteries resulted in significantly increased wall thickness by
8 weeks, despite similar external diameter. Arterial wall struc-
ture was disrupted, with fragmentation of elastic fibers and
irregular distribution of collagen type I fibers. After stopping
treatment, the rats gradually began to show poor health and all
had died by 1 year of age, while all 1-year-old control SHR fe-
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males were in good health. The cause of morbidity and mortality
in the rats treated in early life was clearly malignant hyperten-
sion. Severe hypertrophy of renal arterioles was found, as well
as cerebral hemorrhage.
Conclusion. Despite initial normalization of blood pressure
interference with the renin-angiotensin system during a crucial
stage of development in SHR can initiate marked smooth mus-
cle cell hyperplasia and disruption of the wall structure of the
intrarenal arteries. Subsequent progression of this intrarenal
process after cessation of treatment suggests an independent
process that eventually results in malignant hypertension and
early death.
Multiple studies have reported that transient inhibi-
tion of the renin-angiotensin system from 2 weeks of age
in spontaneously hypertensive rats (SHR), either with
angiotensin-converting enzyme (ACE) inhibitors or with
angiotensin II type 1 (AT1) receptor antagonists, blunts
the increase in blood pressure for up to 21 weeks after
cessation of treatment [1]. However, the change in blood
pressure in comparison to age-matched untreated SHR
averaged 14% ± 6%, ranging from no change to a de-
crease of 25%, and even this effect usually waned over
time.
Permanent treatment of SHR from conception on-
wards with ACE inhibitors completely prevents hy-
pertension [2, 3]. On the other hand, exposure of
normotensive rats to ACE inhibitors from birth to 2
or 3 weeks of age causes hypertrophy of intrarenal
arteries [4, 5]. Similar defects have been found in knock-
out mice lacking angiotensinogen, ACE, or AT1 re-
ceptors [6–9]. Recently, Inokuchi et al [10] studied the
morphology of the intrarenal arteries of AT1a recep-
tor null mice in more detail and found hyperplasia of
the vascular smooth muscle cells, loss of circular me-
chanical integrity, and increased extracellular matrix [10].
Exposure of very young SHR to ACE inhibitor or an
AT1 antagonist could well result in similar detrimental
effects on morphology of the intrarenal arteries if the
beneficial hemodynamic effect is offset by these morpho-
logic abnormalities. In the long-term, such effects on the
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intrarenal arteries could be detrimental with respect to
kidney damage, blood pressure, and survival. Although
the studies where SHR were exposed to ACE inhibition
from conception onwards demonstrated protection from
hypertension-induced changes in the heart and large ar-
teries, the renal vasculature was not studied and follow-up
did not extend beyond 6 months of age [2, 3].
We postulated that while brief exposure to ACE in-
hibitors or AT1 receptor antagonists in young SHR would
temporarily decrease blood pressure, it would also be
associated with the development of intrarenal arterial
malformation, and ultimately have deleterious long-term
effects and decreased survival. Because treatment from
2 to at least 6 weeks of age appears to be the minimum
required to blunt the increase in blood pressure in SHR
[1], treatment was continued in and shortly beyond this
period. Therefore, we examined the direct effects in SHR
of ACE inhibitors and AT1 receptor antagonists adminis-
tered from the last week of gestation until 8 weeks of age
on intrarenal arterial morphology. After stopping treat-




Pregnant SHR (Harlan-Olac, Blackthorn, Bichester,
Oxon, UK) were kept at an ambient temperature of 22◦C,
humidity 60%, exposed to a 12-hour light/dark cycle. Rats
were fed a standard natural diet (RMH-TH, Hope Farms,
Woerden, The Netherlands). Sentinel animals housed in
the same conditions were monitored regularly for infec-
tion with nematodes and pathogenic bacteria and anti-
bodies to rodent viral pathogens (ICLAS, Nijmegen, The
Netherlands).
During the last 7 days of pregnancy and throughout
lactation pregnant rats received either tap water (con-
trol), or the ACE inhibitor captopril (1000 mg/L) or the
AT1 receptor antagonist losartan (500 mg/L) dissolved
in drinking water. This realized a dose of captopril of
100 mg/kg/day and a dose of losartan of 50 mg/kg/day.
Captopril was obtained from Sigma Chemical Co. (St.
Louis, MO, USA), and R.D. Smith, Ph.D. (DuPont-Merck
Pharmaceuticals) kindly provided losartan. All litters
were carried to full gestation; the total number of pups
(male and female) varied from 5 to 15 per litter. Pups
were sacrificed at weaning (4 weeks), or were contin-
ued on treatment until sacrifice at 8 weeks. In the pups
that continued to receive treatment, the dose was main-
tained; the drug concentration in drinking water was ad-
justed according to changes in water intake of the rapidly
growing pups. Female offspring not sacrificed at 8 weeks
(eight controls, six captopril, and five losartan) were no
longer treated and followed until moribund. Pups were
weighed weekly beginning with 4 weeks of age. Systolic
blood pressure was measured from 8 weeks of age by the
tail-cuff method (IITC, San Diego, CA, USA). At 4 and
8 weeks and at regular intervals when off-treatment rats
were placed in metabolic cages for 24 hours for urine col-
lection. At 4 and 8 weeks, some rats were anesthetized
(pentobarbital sodium, 60 mg/kg intraperitoneally) and
killed either by exsanguination or by perfusion fixation
with 1.5% glutaraldehyde in 0.1 mol/L phosphate buffer
at pH 7.4 at 200 mm Hg for morphometry and ultra-
structural evaluation. Kidneys and heart were removed
and weighed. Plasma and urinary creatinine, and urinary
sodium, potassium, osmolality, and protein were deter-
mined by standard techniques.
Renal and cerebral morphology
High-resolution T2-weighted spin-echo images of the
brain (61 slices of 0.5 mm; repetition time 3 seconds;
echo time 17.5 mseconds; field of view 2 × 2 cm; ma-
trix 128 × 128) were collected on a 4.7 Tesla horizontal
bore nuclear magnetic resonance (NMR) spectrometer
(Varian, Palo Alto, CA, USA). The kidneys and the
brain were immersion-fixed in phosphate-buffered saline
(PBS) formaldehyde (4%, pH 7.35) and embedded in
paraffin. Sections stained with hematoxylin-eosin (H&E)
and periodic-acid Schiff (PAS) were examined by light
microscopy. Ultrastructural evaluation was performed in
losartan-treated and control male SHR. Small blocks of
renal tissue (2 × 3 mm) were postfixed in OSO4 (1%
for 2 hours) and subsequently dehydrated and embed-
ded into Epon by standard procedures. Semithin sections
(1 lm thick) were cut on an ultramicrotome using a di-
amond knife, stained as described [11], and examined
by light microscopy. In sections of three to four blocks
of each animal, all profiles of intracortical arteries were
photographed (six to eight per animal), arcuate arteries at
the corticalmedullary border as well as afferent arterioles
were excluded. In all perpendicularly or obliquely sec-
tioned profiles of intracortical arteries the outer and inner
diameters were measured twice, and the mean wall thick-
ness was calculated. In obliquely sectioned profiles, the
shortest outer and corresponding inner diameters were
measured [10]. Analysis on the electron microscopic level
was performed in a qualitative way. From areas of interest
selected in the semithin sections, ultrathin section were
cut and studied with a Philips 301 electron microscope.
Calculations and statistical analyses
Values are expressed as mean ± SEM. Data were
compared with unpaired t test and two-way analysis of
variance (ANOVA) for repeated measurements where
appropriate. Linear regression analysis was employed to
examine the correlation between wall thickness and outer
arterial diameter.
Racasan et al: Lorartan and captopril induce hypertension despite initial normotension 577
100









Control (N = 8)
Captopril (N = 6)
Losartan (N = 5)
Fig. 1. Systolic blood pressure in female control spontaneously hyper-
tensive rats (SHR) and SHR treated for 2 weeks in utero and up to
8 weeks of age.
RESULTS
Functional studies
At 8 weeks of age, systolic blood pressure was reduced
from 187 ± 8 mm Hg in control SHR to 118 ± 5 mm
Hg in captopril-treated SHR and 120 ± 9 mm Hg in
losartan-treated SHR (Fig. 1). Changes in systolic blood
pressure at 8 weeks of age correlated with heart weight
(Table 1). However, by 30 weeks, systolic blood pressure
was at control SHR level (Fig. 1). Treatment with either
captopril or losartan tended to increase daily water intake
and diuresis and reduce urinary osmolality, the difference
being significant by 8 weeks of age (Table 1). There was
no significant effect of captopril on plasma creatinine, but
losartan caused a slight increase. No effect was observed
on sodium and potassium handling (not shown), and none
of the 8-week-old rats developed proteinuria (Table 1).
However, after stopping treatment, mild proteinuria de-
veloped with a maximum varying from 20 to 56 mg/day
vs. 5 to 7 mg/day in 42-week-old control SHR (P < 0.05).
Morphologic studies
Losartan treatment during pregnancy and lactation re-
duced kidney weight (Table 2). At 4 weeks of age in the
losartan-treated SHR, hypertrophy of the media of re-
nal arteries and arterioles was observed (Fig. 2). This was
more pronounced at 8 weeks. Marked smooth muscle cell
hyperplasia of cortical arteries was observed, particularly
at 8 weeks (Fig. 3A vs. B). This resulted in a significantly
increased wall thickness by 8 weeks (Table 2), despite
similar external diameter (Fig. 3C). At the ultrastructural
level, pronounced disruption of the preglomerular arte-
rial wall structure was observed at 8 weeks. Note that
this was in the presence of a systolic blood pressure of
about 120 mm Hg (Fig. 1). At variance with control SHR,
fragmentation of the elastic layers was observed in the
losartan-treated SHR, and the media of interlobular ar-
Table 1. Body and heart weight and renal water handling in control





Number 9 5 7
Body weight g 37 ± 1 41 ± 2 41 ± 3
Heart weight 0.53 ± 0.02 0.47 ± 0.02 0.50 ± 0.01
% body weight
Diuresis 93 ± 5 125 ± 7a 91 ± 8
mL/kg/day
Plasma creatinine 54 ± 1 49 ± 3 59 ± 7
lmol/L
Proteinuria 2.3 ± 0.5 2.4 ± 0.9 1.4 ± 0.2
mg/day
Urine osmolality 1298 ± 148 1316 ± 71 1517 ± 68
mOsm/kg
Age 8 weeks
Number 8 6 5
Body weight g 157 ± 5 159 ± 2 147 ± 11
Heart weight 0.41 ± 0.01 0.36 ± 0.01a 0.36 ± 0.01a
% body weight
Diuresis 65 ± 11 103 ± 9a 113 ± 14a
mL/kg/day
Plasma creatinine 52 ± 4 60 ± 2 66 ± 4a
lmol/L
Proteinuria 4.8 ± 0.7 4.3 ± 1.4 2.5 ± 0.2
mg/day
Urine osmolality 1478 ± 133 996 ± 100a 1070 ± 201a
mOsm/kg
aP < 0.05 vs. age-matched controls.
Table 2. Morphometric analysis of proximal interlobular arteries in
control and losartan-treated young male spontaneously hypertensive
rats (SHR)
Control SHR Losartan-treated SHR
Age 4 weeks
Number 4 4
Left kidney weight 0.68 ± 0.03 0.56 ± 0.02a
% body weight
Outer diameter lm 34.2 ± 2.0 41.5 ± 7.0
Wall thickness lm 4.81 ± 0.32 5.29 ± 0.90
Age 8 weeks
Number 4 4
Left kidney weight 0.46 ± 0.01b 0.39 ± 0.03a,b
% body weight
Outer diameter lm 47.5 ± 6.3 58.6 ± 3.2
Wall thickness lm 4.88 ± 0.38 8.96 ± 1.16a,b
aP < 0.05 vs. age-matched controls.
bP < 0.05 vs. 4 weeks of age.
teries contained abundant type I collagen with character-
istic periodic banding, distributed in an irregular pattern
(Fig. 4A vs. B to D).
Survival
After stopping treatment, the rats gradually began to
show signs of poor health: ruffled hair, weight loss, and
100% mortality by 1 year of age. All 1-year-old control
SHR females were still alive and in good health (Fig. 5).
The cause of morbidity and mortality in the perinatally
treated rats was clearly malignant hypertension. Very
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A B
Fig. 2. At 4 weeks of age, hypertrophy of the media of renal arteries and
arterioles was observed in losartan-treated spontaneously hypertensive
rats (SHR) (A) as compared to control SHR (B).
severe hypertrophy of renal arteries and arterioles, and
occasional fibrinoid necrosis of glomeruli was found
(Fig. 6). Postmortem analysis of rats of 30 weeks and older
of the cerebrum with magnetic resonance imaging (MRI)
revealed hypointense areas in the basal ganglia in the four
rats that could be studied (Fig. 7A). This is caused by the
T2 shortening effect of iron. The presence of hemorrhage
at these locations was confirmed by histology (Fig. 7B).
DISCUSSION
Exposure of young SHR to ACE inhibitors or AT1 an-
tagonists indeed results in a temporary decrease in blood
pressure. However, already at 8 weeks of age, the de-
creased blood pressure is accompanied by severe dis-
ruption of the normal vascular architecture of intrarenal
arteries and arterioles. Ultrastructural changes at 8 weeks
included media hypertrophy due to smooth muscle cell
hyperplasia, fragmentation of elastic fibers, and irregu-
lar distribution of type I collagen fibers. Moreover, these
intrarenal defects became progressively more severe. Ini-
tially in the presence of normal blood pressure, but later,
after exposure to these agents was stopped, in the pres-
ence of high blood pressure, ultimately the rats died
showing symptoms, both renal and extrarenal, of ma-
lignant hypertension between 8 and 12 months of age.
Apparently, interference with the renin-angiotensin sys-
tem during a crucial stage of development in SHR can
initiate this disturbance. Subsequently this intrarenal
process progresses despite cessation of antihypertensive
treatment.
Transient exposure to ACE inhibitors or AT1 antago-
nists from 2 to 20 weeks of age in SHR has repeatedly
been reported to blunt the increase in blood pressure
for months after cessation of treatment [1, 12–14]. Re-
nal arterial resistance was also reported to be decreased
15 weeks after treatment for 2 to 10 weeks of age [12].
In other studies permanent treatment of SHR from con-
ception onwards with ACE inhibitors or AT1 antagonists
completely prevented hypertension and the accompany-
ing left ventricular hypertrophy [2, 13, 15, 16]. However,
the kidney was not investigated in any of these studies and

























Fig. 3. Cross sections of cortical radial arteries in 8-week-old male con-
trol (A) and losartan-treated spontaneously hypertensive rats (SHR)
(B) (1 lm Epon section, bar length 10 lm). (C) Wall thickness in relation
to arterial diameter in arteries in male control SHR (•) and losartan-
treated SHR () at 8 weeks of age.
these studies included a long-term follow-up to evaluate
target organ damage or survival.
Findings in SHR in the current study suggest that, al-
though normal blood pressure was maintained by cap-
topril treatment throughout the period of observation in
the study by Lee et al [2], this probably occurred in the





Fig. 4. Transmission electron micrographs of cortical radial artery wall
structure in (A) control male spontaneously hypertensive rats (SHR)
and (B to D) losartan-treated male SHR at 8 weeks of age. The artery
in (B) has six to seven layers of smooth muscle cells compared to two
layers in (A). Moreover (B) lacks a clear internal and external elas-
tic layer as seen in (A); instead elastic tissue (arrow) together with
collagenous fibers (arrowhead) are found throughout the entire media
between the smooth muscle cells (bar length 5 lm). (C) shows an area
between two smooth muscle cells (corresponding to an area labeled in
(B) by an arrowhead) with abundant type I collagen fibers (bar length
1 lm). The high power electron microscope in (D), quadrangle in (C),
clearly demonstrates the banded pattern of type I collagen (60 to 70 nm










Control (N = 8)
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Fig. 5. Survival in female control spontaneously hypertensive rats
(SHR) and SHR treated for 2 weeks in utero and up to 8 weeks of
age.
A B
Fig. 6. Malignant hypertension lesions in female spontaneously hyper-
tensive rats (SHR) treated for 2 weeks in utero and up to 8 weeks of
age or 30 weeks and older, displaying very severe hypertrophy of renal
arterioles (A) as compared to control female SHR of 48 weeks of age
(B).
A B
Fig. 7. Cerebral magnetic resonance imaginag (MRI) and histology.
Postmortem analysis of the cerebrum of a female spontaneously hyper-
tensive rat (SHR) of 40 weeks treated with captopril for 2 weeks in utero
and up to 8 weeks of age. MRI revealed hypointense areas (arrows) in
the basal ganglia (A). This is caused by the T2 shortening effect of iron.
The presence of hemorrhage at these locations (arrow) was confirmed
by histology (B).
presence of profound intrarenal vascular changes. In
some of these previous studies [13, 15] groups were
included where captopril treatment was stopped at 2
months of age, a design quite similar to the present study.
However, these rats were also not followed until sponta-
neous death, but sacrificed at 8 to 10 months of age. In
contrast to the present study, these studies reported that
blood pressure was 30 mm Hg lower after cessation of
treatment and no morbidity was observed. It is possible
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that a longer period of observation would have exposed
pathology similar to what we observed in the present
study. Indeed, Lan et al [17] reported rebound of hyper-
tension and 100% mortality by 52 weeks of age in SHR
administered an ACE inhibitor, perindopril, from either
4 to 10 or 4 to 20 weeks of age. However, the latter study
also lacks information on renal or extrarenal pathology.
Thus the present study uncovers an important paradox in
SHR. On the one hand, interference with angiotensin II
formation and AT1 receptor-mediated actions early in life
resulted in long-term beneficial systemic hemodynamics.
On the other hand, severe intrarenal vascular abnormal-
ities developed.
Inhibition of the renin-angiotensin system in young
SHR induced a defect in the capacity to concentrate urine,
confirming previous observations in normotensive rats
and piglets [4, 5, 18, 19]. However, this defect is much
milder than the lack of concentrating ability observed in
ACE knockout mice [8, 20]. The treated SHR also did
not show obvious abnormality of the renal papilla, as is
common in the knockout mice, and in human neonates
exposed to ACE inhibitors [21–23]. Whether this partial
maintenance of medullary function in our study is related
to the species or to residual angiotensin activity in this
compartment is not clear.
The pathogenesis of the intrarenal arteriolar changes
is unknown. The most notable change found was
pronounced hyperplasia of smooth muscle cells and
disrupted architecture of the media. This is paradoxic
because stimulation of the AT1 receptor on vascular
smooth muscle cells has well-known proliferative and hy-
pertrophic effects [24–27]. Up-regulation of the number
of AT1 binding sites in the neonatal SHR kidney [28, 29]
may explain the marked sensitivity to these deleterious
effects. Apparently, inhibition of the generation or effects
of angiotensin in a crucial developmental stage stimulates
the uncontrolled production of a different trophic factor
that is normally down regulated by angiotensin. The na-
ture of this factor is enigmatic.
Perinatal exposure of normotensive rats to ACE in-
hibitors at very high doses also causes hypertrophy of in-
trarenal arteries [4, 5]. However, detailed morphologic
information is not available. Intima hyperplasia of in-
trarenal arteries was observed in renal allografts in rats
treated for 34 weeks with an ACE inhibitor or an AT1 an-
tagonist [30]. Similar gross changes have been found in
knockout mice lacking angiotensinogen, ACE, or AT1
receptors [6–9, 20]. Recently, the ultrastructure of in-
trarenal arteries of adult knockout mice lacking AT1a re-
ceptors was studied [10]. Although wall thickening was
also observed, this was mainly caused by the appearance
of additional populations of luminal and abluminal cells
outside more or less intact elastic laminas, although there
were some irregular intercalated elastic fibers among the
smooth muscle cells. Thus the phenotype of the intrarenal
arteries in SHR treated at an early age with AT1 blockade
was more disturbed than that in knockout mice lacking
AT1a receptors. Besides the species difference, another
obvious difference is blood pressure, which at 8 weeks
in the losartan-treated SHR, although reduced to 120 ±
9 mm Hg, was considerably higher than the 87 ± 8 mm
Hg measured in AT1 knockout mice [31]. Recent find-
ings, however, have shown that in ACE knockout mice
the renal structural defects are not necessarily associated
with hypotension. Selective expression of germinal ACE
in ACE knockout mice restored normal kidney structure
despite persistent hypotension [32].
Intracardiac injection of ACE and AT1 receptor an-
tisense cDNA to 5-day-old SHR has successfully been
applied to prevent the development of hypertension, re-
nal, and cardiovascular pathophysiologic changes on a
long-term basis [33–36]. Due to the retrovirus-mediated
transfer, the antisense cDNA was even incorporated into
the germ line and transmitted to the offspring that also
demonstrated marked reduction of blood pressure [37].
Nevertheless, both the neonatally treated parents as well
as the F1 and F2 offspring demonstrated blood pressures
that were still higher than those found in normotensive
Wistar-Kyoto (WKY) rats and showed a reduction of
blood pressure after an intravenous injection of losartan.
Combination of these findings in SHR with data obtained
in the present study indicates that some limited degree of
AT1 receptor activation is needed for the development
of normal vasculature.
CONCLUSION
In summary, despite initial normalization of blood
pressure, transient exposure to ACE inhibitors or AT1
antagonists in young SHR lead to severe smooth mus-
cle cell hyperplasia, and disruption of the intrarenal
vascular architecture. Ultimately this resulted in malig-
nant hypertension. Furthermore, this study revealed that
interference with angiotensin II formation and AT1
receptor-mediated actions early in life leads to a para-
doxic situation of intrarenal vascular smooth muscle
hyperplasia, suggesting another trophic factor that is in-
hibited by angiotensin II under physiologic conditions.
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